The recent biotech IPO surge continues. Ovid Therapeutics raised $75 million in an IPO late Thursday, becoming the fifth life sciences company to hit the Nasdaq in the past two weeks.
Ovid (NASDAQ: OVID), a New York company developing drugs for rare brain diseases, sold 5 million shares at $15 apiece. Those numbers come in at the low end of the projected $15 to $17 per share range set by Ovid, which is run by ex-Teva Pharmaceutical and Bristol-Myers Squibb executive Jeremy Levin. The company will begin trading on the Nasdaq on Friday under the ticker symbol “OVID.”
Ovid follows… Read more »
May 05, 2017 at 05:37AM
from Ben Fidler
No comments:
Post a Comment